Invasive aspergillosis in the setting of cardiac transplantation

被引:73
作者
Montoya, JG
Chaparro, SV
Celis, D
Cortés, JA
Leung, AN
Robbins, RC
Stevens, DA
机构
[1] Stanford Univ, Sch Med, Dept Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Dept Radiol, Stanford, CA 94305 USA
[3] Stanford Univ, Sch Med, Dept Cardiothorac Surg, Stanford, CA 94305 USA
[4] Santa Clara Valley Med Ctr, Dept Med, San Jose, CA 95128 USA
[5] Palo Alto Med Fdn, Res Inst, Palo Alto, CA 94301 USA
[6] Univ Nacl Colombia, Bogota, Colombia
关键词
D O I
10.1086/376527
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Among patients undergoing heart transplantation, Aspergillus is the opportunistic pathogen with the highest attributable mortality. The median time of onset from transplantation for invasive pulmonary aspergillosis (IPA) was 46 days, but the median time to first positive culture result was 104 days among patients with Aspergillus colonization but no invasive disease. Most patients with IPA presented with fever and cough within the first 90 days of transplantation and with single or multiple pulmonary nodules. None of the heart transplant recipients with either IPA or invasive extrapulmonary aspergillosis (IEPA) had associated neutropenia. Human leukocyte antigen A1 locus was found significantly more frequently among patients colonized with Aspergillus than among patients with IPA (P<.006) or IEPA (P<.001). Even in the absence of neutropenia, IPA should be suspected for heart transplant recipients who have fever and respiratory symptoms within the first 3 months of transplantation, have a positive result of culture of respiratory secretions, and have abnormal radiological findings (particularly nodules).
引用
收藏
页码:S281 / S292
页数:12
相关论文
共 38 条
[1]   Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].
Ascioglu, S ;
Rex, JH ;
de Pauw, B ;
Bennett, JE ;
Bille, J ;
Crokaert, F ;
Denning, DW ;
Donnelly, JP ;
Edwards, JE ;
Erjavec, Z ;
Fiere, D ;
Lortholary, O ;
Maertens, J ;
Meis, JF ;
Patterson, TF ;
Ritter, J ;
Selleslag, D ;
Shah, PM ;
Stevens, DA ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14
[2]  
Baumgartner W A, 1979, Curr Probl Surg, V16, P1, DOI 10.1016/S0011-3840(79)80010-6
[3]  
BAUMGARTNER WA, 1978, J THORAC CARDIOV SUR, V75, P525
[4]   INTRA-CRANICAL INFECTION IN CARDIAC TRANSPLANT RECIPIENTS [J].
BRITT, RH ;
ENZMANN, DR ;
REMINGTON, JS .
ANNALS OF NEUROLOGY, 1981, 9 (02) :107-119
[5]   Invasive aspergillosis in the immunocompromised host: Utility of computed tomography and bronchoalveolar lavage [J].
Brown, MJ ;
Worthy, SA ;
Flint, JDA ;
Muller, NL .
CLINICAL RADIOLOGY, 1998, 53 (04) :255-257
[6]   Th1 and Th2 cytokines in mice with invasive aspergillosis [J].
Cenci, E ;
Perito, S ;
Enssle, KH ;
Mosci, P ;
Latge, JP ;
Romani, L ;
Bistoni, F .
INFECTION AND IMMUNITY, 1997, 65 (02) :564-570
[7]  
Chauhan B, 1997, J IMMUNOL, V159, P4072
[8]   Evidence for the involvement of two different MHC class II regions in susceptibility or protection in allergic bronchopulmonary aspergillosis [J].
Chauhan, B ;
Santiago, L ;
Hutcheson, PS ;
Schwartz, HJ ;
Spitznagel, E ;
Castro, M ;
Slavin, RG .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 106 (04) :723-729
[9]   T cell subsets, epitope mapping, and HLA-restriction in patients with allergic bronchopulmonary aspergillosis [J].
Chauhan, B ;
Knutsen, AP ;
Hutcheson, PS ;
Slavin, RG ;
Bellone, CJ .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (10) :2324-2331
[10]   Pneumonia after heart transplantation:: A multiinstitutional study [J].
Cisneros, JM ;
Muñoz, P ;
Torre-Cisneros, J ;
Gurgui, M ;
Rodriguez-Hernandez, MJ ;
Aguado, JM ;
Echaniz, A .
CLINICAL INFECTIOUS DISEASES, 1998, 27 (02) :324-331